136 related articles for article (PubMed ID: 31910997)
1. Pharmacometric Analysis of IgPro10 in Japanese and Non-Japanese Patients With Primary Immunodeficiency.
Luo D; Baheti G; Tortorici MA; Hofmann J; Rojavin MA
Clin Ther; 2020 Jan; 42(1):196-209.e5. PubMed ID: 31910997
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency.
Wasserman RL; Melamed I; Nelson RP; Knutsen AP; Fasano MB; Stein MR; Rojavin MA; Church JA
Clin Pharmacokinet; 2011 Jun; 50(6):405-14. PubMed ID: 21553933
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic properties of Privigen
Morio T; Baheti G; Tortorici MA; Hofmann J; Rojavin MA
Immunol Med; 2019 Dec; 42(4):162-168. PubMed ID: 31847720
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic modeling and simulation of subcutaneous and intravenous IgG dosing in patients with primary immunodeficiency diseases.
Navarro-Mora G; Alberti JJ; Mondou E; Vilardell D; Vicente Torres J; Ayguasanosa J; Páez A
Int Immunopharmacol; 2022 Mar; 104():108472. PubMed ID: 35008008
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic analysis of weekly and biweekly IgPro20 (Hizentra®) dosing in patients with primary immunodeficiency.
Zhang Y; Baheti G; Chapdelaine H; Hofmann J; Rojavin M; Tortorici M; Haddad E
Int Immunopharmacol; 2020 Apr; 81():106005. PubMed ID: 31806567
[TBL] [Abstract][Full Text] [Related]
6. Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin.
Li Z; McCoy B; Engl W; Yel L
J Clin Immunol; 2021 Aug; 41(6):1331-1338. PubMed ID: 34036490
[TBL] [Abstract][Full Text] [Related]
7. Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiency.
Tortorici MA; Lawo JP; Weide R; Jochems J; Puli S; Hofmann J; Pfruender D; Rojavin MA
Int Immunopharmacol; 2019 Jan; 66():119-126. PubMed ID: 30447530
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases.
Dumas T; Berry NS; Wolfsegger M; Jolles S; McCoy B; Yel L
Int Immunopharmacol; 2019 Jun; 71():404-410. PubMed ID: 30952104
[TBL] [Abstract][Full Text] [Related]
9. Integrated population pharmacokinetics of immunoglobulin G following intravenous or subcutaneous administration of various immunoglobulin products in patients with primary immunodeficiencies.
Li Z; Follman K; Freshwater E; Engler F; Yel L
Int Immunopharmacol; 2022 Dec; 113(Pt A):109331. PubMed ID: 36461591
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of immunoglobulin G after intravenous, subcutaneous, or hyaluronidase-facilitated subcutaneous administration in immunoglobulin-naive patients with primary immunodeficiencies.
Li Z; Follman K; Freshwater E; Engler F; Yel L
Int Immunopharmacol; 2024 Feb; 128():111447. PubMed ID: 38185032
[TBL] [Abstract][Full Text] [Related]
11. Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases.
Li Z; Follman K; Freshwater E; Engler F; Yel L
J Clin Immunol; 2023 Nov; 43(8):2127-2135. PubMed ID: 37773562
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency.
Wasserman RL; Church JA; Peter HH; Sleasman JW; Melamed I; Stein MR; Bichler J;
Eur J Pharm Sci; 2009 Jun; 37(3-4):272-8. PubMed ID: 19491015
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of IgPro10 in Japanese primary immunodeficiency patients: a registrational study.
Morio T; Gotoh K; Imagawa T; Morita K; Ohnishi H; Yasui K; Hofmann J; Lawo JP; Shebl A; Rojavin MA
Int J Hematol; 2021 Jun; 113(6):921-929. PubMed ID: 33738703
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases.
Kanegane H; Imai K; Yamada M; Takada H; Ariga T; Bexon M; Rojavin M; Hu W; Kobayashi M; Lawo JP; Nonoyama S; Hara T; Miyawaki T
J Clin Immunol; 2014 Feb; 34(2):204-11. PubMed ID: 24504846
[TBL] [Abstract][Full Text] [Related]
15. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency.
Igarashi A; Kanegane H; Kobayashi M; Miyawaki T; Tsutani K
Clin Ther; 2014 Nov; 36(11):1616-24. PubMed ID: 25236916
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic Analysis of Weekly Versus Biweekly IgPro20 Dosing in Patients With Primary Immunodeficiency.
Rojavin MA; Chapdelaine H; Tortorici MA; Praus M; Baheti G; Zhang Y; Hofmann J; Labrosse R; Dicaire R; Haddad E
Clin Pharmacol Drug Dev; 2020 Aug; 9(6):664-670. PubMed ID: 31814328
[TBL] [Abstract][Full Text] [Related]
17. Facilitated Subcutaneous Immunoglobulin Replacement Therapy in Clinical Practice: A Two Center, Long-Term Retrospective Observation in Adults With Primary Immunodeficiencies.
Wiesik-Szewczyk E; Sołdacki D; Paczek L; Jahnz-Różyk K
Front Immunol; 2020; 11():981. PubMed ID: 32670265
[TBL] [Abstract][Full Text] [Related]
18. Correlations Among Subcutaneous Immunoglobulin Dosage, Immunoglobulin G Serum Pre-infusional Levels and Body Mass Index in Primary Antibody Deficiency Patients: A Pooled Analysis from the SHIFT/IBIS Studies.
Pecoraro A; Ricci S; Vultaggio A; Boggia GM; Spadaro G;
Clin Drug Investig; 2020 Mar; 40(3):279-286. PubMed ID: 32036588
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic modelling of intravenous immunoglobulin in patients with predominantly antibody deficiencies.
Lee JL; Mohd Saffian S; Makmor-Bakry M; Islahudin F; Alias H; Noh LM; Ismail IH; Mohamed Shah N
Br J Clin Pharmacol; 2021 Jul; 87(7):2956-2966. PubMed ID: 33377197
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic simulation of varied Immune Globulin Subcutaneous (Human), 20% solution (Ig20Gly) loading and maintenance dosing regimens in immunoglobulin-naïve patients with primary immunodeficiency diseases.
Li Z; Dumas T; Seth Berry N; McCoy B; Yel L
Int Immunopharmacol; 2021 Nov; 100():108044. PubMed ID: 34601202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
